Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Autor:
Heung Tae Kim, Ji-Youn Han, Youngjoo Lee, Jin Soo Lee, Byung-Ho Nam, Hyae Young Kim, Hye Jin An, Geon Kook Lee
Publikováno v:
Clinical Lung Cancer. 21:e572-e582
Background We aimed to evaluate whether intercalated combination of EGFR tyrosine kinase inhibitor gefitinib and chemotherapy improves survival outcomes in never-smokers with advanced lung adenocarcinoma. Patients and Methods Never-smokers with chemo
Autor:
Ryoko Suzuki, Steven H. Lin, Xiong Wei, Ritsuko Komaki, Pamela K. Allen, James D. Cox, James W. Welsh
Publikováno v:
Clinical Lung Cancer. 19:e885-e891
Purpose Acute esophagitis is common after thoracic radiation therapy (TRT) given with chemotherapy for limited-stage small-cell lung cancer (LS SCLC). Although twice-daily TRT to 45 Gy in 30 fractions is considered standard, some clinicians are reluc
Autor:
Seung Joon Kim, Jae Young Hur, Jae Cheol Lee, Chang-Min Choi, Min Ki Lee, In-Jae Oh, Cheol-Kyu Park, Kye Young Lee, Hee Joung Kim, Young-Chul Kim
Publikováno v:
Clinical Lung Cancer. 19:e775-e781
Introduction HER2 mutations are found in 2% to 4% of non–small-cell lung cancer cases and are usually mutually exclusive with other genetic alterations. We screened a large cohort of patients from multiple institutions in Korea, described the chara
Autor:
Geoffrey R. Oxnard, Andrew Weickhardt, D. Ross Camidge, Lecia V. Sequist, Jean Fan, Pasi A. Jänne, Jeanette Alicea, Elizabeth S. Dowling
Publikováno v:
Clinical Lung Cancer. 19:e655-e665
Background The present phase Ib study assessed the maximum tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of high-dose intermittent (HDI) afatinib monotherapy for patients with advanced solid tumors. The planned focus was pati
Publikováno v:
Clinical Lung Cancer. 19:418-425
The role of positive lymph node location in non-small-cell lung cancer (NSCLC) patients and effects on survival was assessed. A total of 88 operated patients with unsuspected N2 disease or station 10 lymph nodes were included. No difference was found
Autor:
Cha-Mei Tang, Yawei Qiao, Jianzhong He, Vivek Verma, John V. Heymach, Zhongxing Liao, Alexander Augustyn, Anne S. Tsao, Daniel L. Adams, Steven H. Lin
Publikováno v:
Clinical lung cancer. 22(3)
Background Cancer-associated macrophage-like cells (CAMLs) are a potential peripheral blood biomarker for disease progression. This study used data from a phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally advanced non–small
Autor:
Saiama N. Waqar, Rachel E. Sanborn, Susanne M. Arnold, Maria Q. Baggstrom, John L. Villano, Maurice Willis, John T. Hamm, Michael A. Thompson, Markos Leggas, Kari Chansky, Joseph Grant F Rosales, John Crowley
Publikováno v:
Clinical lung cancer. 21(4)
Introduction The purpose of this study was to evaluate the efficacy and tolerability of carfilzomib plus irinotecan (C/I) in patients with relapsed small-cell lung cancer (SCLC). Patients and Methods Patients with SCLC who progressed after 1 platinum
Autor:
Laurent Gressot, M. Wolfsteiner, Mark A. Socinski, Ray D. Page, Davey B. Daniel, Jeanna Knoble, David R. Spigel, Cesare Gridelli, Santiago Ponce Aix, Teng Jin Ong, Robert M. Jotte, Michael McCleod, Michael Thomas, Niels Reinmuth, Howard Jack West, O. Juan-Vidal, Kathryn F Mileham, Tianlei Chen, Rafia Bhore, Daniel Morgensztern
Publikováno v:
Clinical Lung Cancer. 22:6-15.e4
Background We evaluated maintenance nanoparticle albumin-bound (nab) paclitaxel in the treatment of advanced squamous non–small-cell lung cancer. Patients and Methods Patients with treatment-naive squamous non–small-cell lung cancer received four
Autor:
Xiaofei Wang, Stephanie Duong, Hossein Borghaei, Lin Gu, Robert A. Kratzke, Arkadiusz Z. Dudek, Everett E. Vokes, Hedy L. Kindler, Thomas E. Stinchcombe
Publikováno v:
Clin Lung Cancer
The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of pemetrexed after first-line pemetrexed and platinum would improve progression-free survival
Autor:
Ronald L. Burkes, Anwar Hossain, Quincy Chu, Andrea Bezjak, Robert MacRae, Neill Iscoe, Andrew Hope, Essai Mahalingam, John R. Goffin, Ronald Feld, Frances A. Shepherd, John Cho, Stephanie Capobianco, Natasha B. Leighl, Anthony Brade, Scott A. Laurie, Alexander Sun
Publikováno v:
Clinical Lung Cancer. 17:133-141
Introduction Concurrent thoracic radiation and platinum-based chemotherapy is the standard of care for treatment of unresectable stage IIIA-IIIB non–small-cell lung cancer (NSCLC), but the optimal drug regimen has not been established. Patients and